In 2026, the clinical role of community pharmacy has reached a new maturity. While Flu and COVID-19 remain vital, the Respiratory Syncytial Virus (RSV) vaccination programme has emerged as a critical intervention for protecting the two most vulnerable cohorts in our communities: older adults and newborn infants.

For the modern pharmacy, an RSV service is more than a revenue stream; it is a vital contribution to population health. However, a successful rollout requires a digital workflow that is as clinically robust as it is efficient.

1. A National Strategy: Maternal Health & Infant Protection

A core pillar of the UK’s national strategy is the protection of infants during their first, most vulnerable months of life. RSV is a leading cause of infant hospitalisation, and the most effective way to prevent this is through maternal immunisation.

Your RSV service should be positioned as a vital gateway for the maternal cohort:

• The 28-Week Milestone: The programme is designed for pregnant individuals from 28 weeks gestation onwards.

• Passive Immunity: By vaccinating at this stage, maternal antibodies are transferred to the unborn baby, providing immediate protection from birth.

• Clinical Timing: While the vaccine can be given up until delivery, the 28-week mark is the clinical "sweet spot" for maximum antibody transfer.

With the Deltera platform, your pharmacy can proactively identify and support this cohort, ensuring that expectant parents have local, convenient access to this life-saving immunisation without needing a GP appointment.

2. An Evidence-Based Framework (Green Book & JCVI)

In a high-scrutiny clinical area like immunisation, "standard" PGDs are not enough. Your clinical framework must be in total lockstep with national health security guidelines.

Deltera’s RSV PGDs are developed by a certified UK-based medical team and are maintained with absolute clinical precision:

• Green Book Chapter 27a: Our PGDs and clinical workflows are updated in real-time to align with Chapter 27a of Immunisation Against Infectious Disease.
• JCVI Alignment: We move in lockstep with the latest JCVI (Joint Committee on Vaccination and Immunisation) statements, ensuring your pharmacy is always working to the most current national recommendations.
• Manufacturer Integration: We maintain relationships with vaccine manufacturers to ensure our protocols reflect the latest safety data and Summary of Product Characteristics (SmPC).

3. Precision Pre-Screening: Managing Older Adult Cohorts

From 1 April 2026, the eligibility for the older adult RSV programme has expanded to include everyone aged 75 and over, including care home residents. Managing this volume requires a triage system that prevents clinical errors.

Deltera provides a dual-pathway for pre-screening:

• Remote Assessment: Patients (or their carers) can complete clinical pre-screening at home. This is especially effective for the 75+ cohort, allowing families to assist with the digital triage before the appointment.
• Smart Flagging: The system automatically cross-references the patient’s age and clinical history against JCVI criteria. If a patient doesn't meet the eligibility threshold, the system alerts the clinician instantly, protecting your staff and your pharmacy’s compliance.

4. Operational Efficiency: The "Single-Entry" Workflow

The biggest barrier to a profitable vaccination service is redundant admin. If your pharmacists are re-keying data for every seasonal jab, your margins are disappearing into paperwork.

The Deltera Efficiency Edge:

• Unified Records: If a patient has previously had a Flu or COVID-19 vaccination at your pharmacy, their record is already live. You simply add the RSV clinical episode to their existing history.
• Zero-Admin GP Notifications: Once the vaccine is administered, the platform automatically generates and sends the notification to the GP surgery. This fulfills your professional obligation without a single minute of manual data entry.
• Audit-Ready Oversight: Every consultation is timestamped and stored. Whether it’s an internal audit or a GPhC inspection, you can pull your entire RSV service record in seconds.

5. Bridging the Gap with the IP Bridge

While national PGDs are designed for the majority, clinical "edge cases" always exist. Perhaps a patient falls just outside the standard age cohort but has a complex respiratory history that warrants protection.

In a traditional PGD model, you would have to turn this patient away. With the Deltera IP Bridge, your Independent Prescribers can step in. They can assess the patient and, where clinically appropriate, move to a Patient Specific Direction (PSD). This ensures the patient receives the care they need while keeping them within your pharmacy’s clinical ecosystem.

Conclusion: Protecting the Future

The RSV programme is a definitive shift toward a more preventative, pharmacy-led healthcare model. By adopting a digital-first approach—supported by the Green Book and JCVI-aligned PGDs—your pharmacy can lead the way in maternal and older adult care.

Ready to launch your RSV service?

‍Empower your team with the most advanced clinical engine in the UK.

‍